Hormone replacement therapy and

KOMULAINEN M, KROGER H, TUPPURAINEN M T, HEIKKINEN A M, ALHAVA E, HONKANEN R, lURVELIN I and SAARiKOSKi s (1999) Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women a population-based 5-year randomized trial. J Clin Endocrinol Metab 84, 546-52. [Pg.103]

Long-term use of hormone-replacement therapy and concurrent use of progestins appear to contribute to breast cancer risk.7 The use of postmenopausal estrogen-replacement therapy in women with a history of breast cancer generally is considered contraindicated. However, most experts believe that the safety and benefits of low-dose oral contraceptives currently outweigh the potential risks and that changes in the prescribing practice for the use of oral contraceptives are not warranted. Oral contraceptives are known to reduce the risk of ovarian cancer by about 40% and the risk of endometrial cancer by about 60%. [Pg.1304]

Bath PMW, Gray LJ (2005) Association between hormone replacement therapy and subsequent stroke a meta-analysis. Br Med J DOhlO.l 136/BMJ.38331.655347.8F... [Pg.238]

Heikkinen AM, Niskanen L, Yla-Herttuala S, Luoma J, Tuppurainen MT, Komu-lainen M, Saarikoski S (1998) Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 29 155-161... [Pg.241]

Perez-Gutthan S, Garcfa-Rodriguez LA, Castellsague J, Duque-Oliart A (1997) Hormone replacement therapy and risk of venous thromboembolism population based case-control study. Br Med J 314 796-800... [Pg.244]

Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women a randomized, controlled trial. J Clin Endocrinol Metab 85 214-218... [Pg.247]

Holli K, Isola J, Cuzick J (1997) Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 350 1704-1705... [Pg.277]

One of the most important areas of synthetic estrogens and progestins are their use as oral contraceptives, for hormone replacement therapy, and as drugs for menstrual disorders. [Pg.365]

The major uses of progestogens are for hormone replacement therapy and for hormonal contraception where they suppress ovulation and make the cervical mucus impenetrable to spermatozoa. Other indications include secondary amenorrhea, dysmenorrhea, infertility and habitual abortion and endometrium suppression in endometriosis. Progestogens are also used for palliation in metastasized endometrial and breast carcinoma. Medrogestone has been used in the treatment of fibroid uterine tumors. [Pg.402]

Zandi PP et al Hormone replacement therapy and incidence of Alzheimer s disease in older women. JAMA 2002 288 2123. [PMID 12413371]... [Pg.927]

Table 2 Some studies of the association between hormone replacement therapy and breast neoplasms ...

Cahill M, O Toole L, Acheson RW. Hormone replacement therapy and retinal vein occlusion. Eye 1999 13(Pt 6) 798-800. [Pg.194]

Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001 86(l) 112-23. [Pg.194]

Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review. Drugs 1994 47(Suppl 2) 16-24. [Pg.196]

Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002 94(7) 497-504. [Pg.197]

Mack TM. Hormone replacement therapy and cancer. Baillieres Clin Endocrinol Metab 1993 7(1) 113-49. [Pg.197]

Brinton LA. Hormone replacement therapy and risk for breast cancer. Endocrinol Metab Clin North Am... [Pg.197]

MacLennan AH. Hormone replacement therapy and the menopause. Australian Menopause Society. Med J Aust 1991 155(1) 43—4. [Pg.198]

Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer results from epidemiologic studies. Am J Obstet Gynecol 1993 168(5) 1473-80. [Pg.198]

Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995 142(8) 788-95. [Pg.198]

Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997 72(5) 758-61. [Pg.198]

Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology results of the Iowa Women s Health Study. JAMA 1999 281(22) 2091-7. [Pg.198]

Fernandez E, Callus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk a systematic analysis from a network of case-control studies. Int J Cancer 2003 105 408-12. [Pg.199]

The associations between hormone replacement therapy and breast, endometrial, and ovarian cancers are discussed in the monograph on estrogens. [Pg.266]

Lloyd G. Hormone replacement therapy and ischaemic heart disease continuing questions but still no answers. Int J Clin Pract 2000 54(7) 416-7. [Pg.270]

Gabriel-Cox K. Hormone replacement therapy and primary prevention alas, again. Prev Cardiol 2003 6 61-2. [Pg.270]

Petitti D. Hormone replacement therapy and coronary heart disease four lessons. Int J Epidemiol 2004 33 461-3. [Pg.270]

Rossouw JE. Hormone replacement therapy and cardiovascular disease. Curr Opin Lipidol 1999 10(5) 429-34. [Pg.270]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...